Eliminating SCID row: new approaches to SCID

Area of Science:

• Immunology
• Hematology
• Pediatric Medicine

Background:

• Severe combined immunodeficiency (SCID) is a lethal primary immune deficiency disorder.
• Hematopoietic stem cell transplantation (HSCT) has transformed SCID treatment, offering good prognoses.
• SCID has been pivotal in advancing HSCT techniques, including matched sibling, haploidentical, and unrelated donor transplants.

Purpose of the Study:

• To review recent advances in allogeneic and autologous HSCT for SCID.
• To discuss ongoing controversies and optimal approaches in HSCT for SCID.
• To explore the role and advancements of gene therapy in SCID treatment.

Main Methods:

• Review of allogeneic HSCT techniques (matched sibling, haploidentical, unrelated donor).
• Analysis of autologous transplantation with ex vivo gene correction (gene therapy).
• Discussion of novel gene therapy approaches, including gene repair using site-specific endonucleases.

Main Results:

• HSCT has led to significant improvements in SCID patient outcomes.
• Gene therapy, particularly vector-mediated gene addition, shows success in specific SCID subtypes (e.g., ADA-SCID, X-linked SCID).
• Newborn screening for SCID is expected to further improve prognoses by enabling early detection and intervention.

Conclusions:

• Optimal HSCT strategies for SCID, including stem cell sources and conditioning, are still being defined.
• Gene therapy presents a promising alternative to allogeneic HSCT, potentially avoiding graft-versus-host disease (GVHD).
• Advancements in gene therapy and widespread newborn screening are poised to enhance SCID patient outcomes significantly.